HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study
出版年份 2021 全文链接
标题
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 39, Issue 13, Pages 1468-1478
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2021-03-26
DOI
10.1200/jco.20.02761
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
- (2020) Willemieke P. M. Dijksterhuis et al. Gastric Cancer
- Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
- (2020) Seiichiro Mitani et al. Cancers
- Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
- (2020) Akitaka Makiyama et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
- (2020) K. Yamaguchi et al. ANNALS OF ONCOLOGY
- HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany
- (2019) Gustavo Baretton et al. VIRCHOWS ARCHIV
- Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma
- (2019) V Gambardella et al. ANNALS OF ONCOLOGY
- A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
- (2019) Tae-Yong Kim et al. Gastric Cancer
- Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: a real‐world evidence study
- (2019) Willemieke P.M. Dijksterhuis et al. INTERNATIONAL JOURNAL OF CANCER
- Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment
- (2019) Chen Xu et al. Aging-US
- Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment
- (2019) Tobias Gutting et al. Journal of Gastrointestinal and Liver Diseases
- Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
- (2018) S T Kim et al. ANNALS OF ONCOLOGY
- Genomic Profiling of HER2‐Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2‐Positive Advanced Gastric Cancer Treated with Trastuzumab
- (2018) Asunción Díaz‐Serrano et al. ONCOLOGIST
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer
- (2018) Xiaomin Fu et al. OncoTargets and Therapy
- Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
- (2018) Shusuke Yagi et al. Gastric Cancer
- mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants
- (2018) Markus Eckstein et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
- (2018) Francisco Sanchez-Vega et al. Cancer Discovery
- Update on Gastroesophageal Adenocarcinoma Targeted Therapies
- (2017) Steven B. Maron et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival
- (2017) Johannes Breyer et al. VIRCHOWS ARCHIV
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
- (2017) Yelena Y. Janjigian et al. Cancer Discovery
- Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
- (2017) Eirini Pectasides et al. Cancer Discovery
- An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
- (2016) G. Piro et al. CLINICAL CANCER RESEARCH
- HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
- (2016) F. Pietrantonio et al. INTERNATIONAL JOURNAL OF CANCER
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical impact of tumour biology in the management of gastroesophageal cancer
- (2016) Florian Lordick et al. Nature Reviews Clinical Oncology
- A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
- (2016) Jun Ho Yi et al. Cancer Research and Treatment
- Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens
- (2015) Sangjeong Ahn et al. Oncotarget
- Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
- (2014) Jihun Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Level ofHER2Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
- (2013) Carlos Gomez-Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
- (2012) Y. Y. Janjigian et al. ANNALS OF ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Her2-Diagnostik beim Magenkarzinom
- (2010) J. Rüschoff et al. PATHOLOGE
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- HER-2 amplification is highly homogenous in gastric cancer
- (2009) Andreas H. Marx et al. HUMAN PATHOLOGY
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now